Drug intelligence / Profile preview

Tunodafil

Development stage: Phase 1
Lead developer: Yangtze River Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Tunodafil is a drug developed by Yangtze River Pharmaceutical Group Co., Ltd. It is currently undergoing clinical investigation, specifically a Phase 1 study, to assess its pharmacokinetic and pharmacodynamic interactions when co-administered with alcohol in healthy Chinese male participants. The study aims to evaluate its effects on blood pressure, pulse rate, and its systemic exposure, including that of its metabolite M459.

Other names: Tunodafil Hydrochloride Tablets

Targets

PDE5A (Cyclic GMP-specific phosphodiesterase 5A)

Beyond the preview

Go deeper on Tunodafil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tunodafil.

Explore the full profile